Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: Experience from the Society of Pediatric Liver Transplantation (SPLIT)
- PMID: 34990053
- DOI: 10.1111/ajt.16945
Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: Experience from the Society of Pediatric Liver Transplantation (SPLIT)
Abstract
Management of unresectable pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) remains challenging. The Society of Pediatric Liver Transplantation (SPLIT) database was used to study survival predictors in pediatric liver transplantation (LT) for HB and HCC. Event-free survival (EFS), associated risk factors, and postoperative complications were studied in children requiring LT for HB/HCC at 16 SPLIT centers. Three-year EFS was 81% for HB (n = 157) and 62% for HCC (n = 18) transplants. Of HB transplants, 6.9% were PRETEXT II and 15.3% were POST-TEXT I/II. Tumor extent did not impact survival (p = NS). Salvage (n = 13) and primary HB transplants had similar 3-year EFS (62% versus 78%, p = NS). Among HCC transplants, 3-year EFS was poorer in older patients (38% in ≥8-year-olds vs 86% <8-year-olds) and those with larger tumors (48% for those beyond versus 83% within Milan criteria, p = NS). Risk of infection (HR 1.5, 95% CI 1.1-2.2, p = .02) and renal injury (HR 2.4, 95% CI 1.7-3.3, p < .001) were higher in malignant versus nonmalignant LT. Survival is favorable for pediatric HB and HCC LT, including outcomes after salvage transplant. Unexpected numbers of LTs occurred in PRE/POST-TEXT I/II tumors. Judicious patient selection is critical to distinguish tumors that are potentially resectable; simultaneously, we must advocate for patients with unresectable malignancies to receive organs.
Keywords: cancer/malignancy/neoplasia; clinical decision-making; clinical research/practice; liver disease: malignant; liver transplantation/hepatology; patient survival; pediatrics.
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons.
References
REFERENCES
-
- Hamilton EC, Balogh J, Nguyen DT, Graviss EA, Heczey AA, Austin MT. Liver transplantation for primary hepatic malignancies of childhood: the UNOS experience. J Pediatr Surg. 2017;53:163-168.
-
- Vinayak R, Cruz RJ Jr, Ranganathan S, et al. Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015). Liver Transpl. 2017;23:1577-1588.
-
- Czauderna P, Haberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92-101.
-
- Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the children’s hepatic tumors international collaboration. Lancet Oncol. 2017;18(1):122-131.
-
- Khan AS, Brecklin B, Vachharajani N, et al. Liver transplantation for malignant primary pediatric hepatic tumors. J Am Coll Surg. 2017;225:103-113.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
